Caris Life Sciences Unveils AI Test Predicting Early and Late Breast Cancer Recurrence in 3 Days
Caris Life Sciences launched Caris MI Clarity, the first AI-powered test predicting both early and late distant recurrence risk at diagnosis for HR-positive/HER2-negative breast cancer, with results in three business days using pathology and clinical data. Caris MI Clarity stratifies patients as Low or High-risk to guide treatment decisions.
1. Launch Details
Caris MI Clarity is the first prognostic assay combining AI analysis of pathology and clinical inputs to predict both early (0–5 years) and late (5–15 years) distant recurrence risk at diagnosis for HR-positive/HER2-negative, node-negative breast cancer. The test delivers results within three business days, compared to several weeks for legacy assays.
2. Data and Validation
The AI model was trained on Caris’ proprietary multi-modal dataset containing tens of thousands of digitized H&E whole-slide images and associated clinical data. Validation utilized samples and outcome data from national clinical trials including TAILORx and NSABP B-42, ensuring robust performance in stratifying recurrence risk.
3. Clinical Implications
By categorizing patients into Low or High risk for both early and late distant recurrence, Caris MI Clarity offers physicians a comprehensive risk profile at diagnosis to inform systemic treatment decisions. This unified approach aims to reduce both overtreatment toxicity and undertreatment risk over the disease continuum.